Top
Achromatopsia - Healing Genes
701
post-template-default,single,single-post,postid-701,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Achromatopsia

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Gene Therapy for Achromatopsia (CNGA3)

An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children With Achromatopsia Owing to Defects in CNGA3


Phase 1/2

DESCRIPTION:

Doctors at the Kellogg Eye Center in Michigan are seeking pediatric patients with Achromatopsia due to specific genetic mutations in the CNGA3 gene. The drug uses a genetic editing tool, delivered only within the retina, designed to eliminate the harmful mutation in the CNGA3 gene. It uses a harmless virus that can selectively pass the corrected gene into the cells of the retina .

Treatment will involve a single injection surgery to the retina at the back of the eye, then follow up for 6 months


PATIENT MUST:

  • Be 3 to 15 years of age
  • Meet genetic screening requirements specific to the study aim
  • Have achromatopsia confirmed by a retinal specialist (CI or PI)

THE STUDY INVOLVES:

  1. Screening before the treatment
  2. A single injection of the genetic therapy to the retina at the back of the eye
  3. Follow up for 1 year

LOCATIONS AND CONTACTS:

The study location is at the Kellogg Eye Center in Ann Arbor, MI. Map.

Contact: MeiraGTx UK II Ltd (International)  |  +44 (0)02 3866 4320 (international) |  [email protected]

 

SPONSOR INFORMATION:

MeiraGTx UK II Ltd

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03758404

 

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader